Literature DB >> 17105746

Neuropathic and cerebrovascular correlates of hearing loss in Fabry disease.

M Ries1, H J Kim, C K Zalewski, M A Mastroianni, D F Moore, R O Brady, J M Dambrosia, R Schiffmann, C C Brewer.   

Abstract

Fabry disease, OMIM 301500, is a progressive multisystem storage disorder due to the deficiency of alpha-galactosidase A (GALA). Neurological and vascular manifestations of this disorder with regard to hearing loss have not been analysed quantitatively in large cohorts. We conducted a retrospective cross sectional analysis of hearing loss in 109 male and female patients with Fabry disease who were referred to and seen at the Clinical Center of the National Institutes of Health, Bethesda, MD, USA on natural history and enzyme replacement study protocols. There were 85 males aged 6-58 years (mean 31 years, SD 13) and 24 females aged 22-72 years (mean 42 years, SD 12). All patients underwent a comprehensive audiological evaluation. In addition, cerebral white matter lesions, peripheral neuropathy, and kidney function were quantitatively assessed. HL(95), defined as a hearing threshold above the 95th percentile for age and gender matched normal controls, was present in 56% [95% CI (42.2-67.2)] of the males. Prevalence of HL(95) was lower in the group of patients with residual GALA enzyme activity compared with those without detectable activity (33% versus 63%) HL(95) was present in the low-, mid- and high-frequency ranges for all ages. Male patients with HL(95) had a higher microvascular cerebral white matter lesion load [1.4, interquartile range (IQR) 0-30.1 +/- versus 0, IQR 0-0], more pronounced cold perception deficit [19.4 +/- 5.5 versus 13.5 +/- 5.5 of just noticeable difference (JND) units] and lower kidney function [creatinine: 1.6 +/- 1.2 versus 0.77 +/- 0.2 mg/dl; blood urea nitrogen (BUN): 20.1 +/- 14.1 versus 10.3 +/- 3.28 mg/dl] than those without HL(95) (P < 0.001). Of the females, 38% had HL(95). There was no significant association with cold perception deficit, creatinine or BUN in the females. Word recognition and acoustic reflexes analyses suggested a predominant cochlear involvement. We conclude that hearing loss involving all frequency regions significantly contributes to morbidity in patients with Fabry disease. Our quantitative analysis suggests a correlation of neuropathic and vascular damage with hearing loss in the males. Residual GALA activity appears to have a protective effect against hearing loss.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17105746      PMCID: PMC1950668          DOI: 10.1093/brain/awl310

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  29 in total

1.  Quantitative sensation testing in epidemiological and therapeutic studies of peripheral neuropathy.

Authors:  P J Dyck; P C O'Brien
Journal:  Muscle Nerve       Date:  1999-06       Impact factor: 3.217

2.  Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females.

Authors:  K D MacDermot; A Holmes; A H Miners
Journal:  J Med Genet       Date:  2001-11       Impact factor: 6.318

3.  Enhanced endothelium-dependent vasodilation in Fabry disease.

Authors:  G Altarescu; D F Moore; R Pursley; U Campia; S Goldstein; M Bryant; J A Panza; R Schiffmann
Journal:  Stroke       Date:  2001-07       Impact factor: 7.914

4.  Screening tympanometry: criteria for medical referral.

Authors:  R H Margolis; J W Heller
Journal:  Audiology       Date:  1987

5.  Enzymatic defect in Fabry's disease. Ceramidetrihexosidase deficiency.

Authors:  R O Brady; A E Gal; R M Bradley; E Martensson; A L Warshaw; L Laster
Journal:  N Engl J Med       Date:  1967-05-25       Impact factor: 91.245

6.  Identification of fifteen novel mutations and genotype-phenotype relationship in Fabry disease.

Authors:  G M Altarescu; L G Goldfarb; K Y Park; C Kaneski; N Jeffries; S Litvak; J W Nagle; R Schiffmann
Journal:  Clin Genet       Date:  2001-07       Impact factor: 4.438

Review 7.  Renal ultrastructural findings in Anderson-Fabry disease.

Authors:  Adalberto Sessa; Antonella Toson; Manuela Nebuloni; Francesco Pallotti; Ferdinando Giordano; Graziana Battini; Alessia Maglio; Mietta Meroni; Gilberto Calconi; Gabriele Bertolone; Pierlucio Gatti
Journal:  J Nephrol       Date:  2002 Mar-Apr       Impact factor: 3.902

8.  Involvement of dorsal root ganglia in Fabry's disease.

Authors:  N Gadoth; U Sandbank
Journal:  J Med Genet       Date:  1983-08       Impact factor: 6.318

9.  Pathophysiologic and ultrastructural basis for intestinal symptoms in Fabry's disease.

Authors:  B D O'Brien; T K Shnitka; R McDougall; K Walker; L Costopoulos; B Lentle; L Anholt; H Freeman; A B Thomson
Journal:  Gastroenterology       Date:  1982-05       Impact factor: 22.682

10.  Patients affected with Fabry disease have an increased incidence of progressive hearing loss and sudden deafness: an investigation of twenty-two hemizygous male patients.

Authors:  Dominique P Germain; Paul Avan; Augustin Chassaing; Pierre Bonfils
Journal:  BMC Med Genet       Date:  2002-10-11       Impact factor: 2.103

View more
  21 in total

1.  Hearing loss in adult patients with Fabry disease treated with enzyme replacement therapy.

Authors:  Eefje B Suntjens; Bouwien E Smid; Marieke Biegstraaten; Wouter A Dreschler; Carla E M Hollak; Gabor E Linthorst
Journal:  J Inherit Metab Dis       Date:  2014-11-14       Impact factor: 4.982

Review 2.  [Females with Fabry's disease - an interdisciplinary diagnostic and therapeutic challenge].

Authors:  Frank Weidemann; Markus Niemann; Claudia Sommer; Meinrad Beer; Frank Breunig; Christoph Wanner
Journal:  Med Klin (Munich)       Date:  2010-09-28

3.  A prospective 10-year study of individualized, intensified enzyme replacement therapy in advanced Fabry disease.

Authors:  Raphael Schiffmann; Caren Swift; Xuan Wang; Derek Blankenship; Markus Ries
Journal:  J Inherit Metab Dis       Date:  2015-04-22       Impact factor: 4.982

4.  Temporal intradiploic dilative vasculopathy: an additional pathogenic factor for the hearing loss in fabry disease?

Authors:  Carla Pinto Moura; Carlos Soares; Daniela Seixas; Margarida Ayres-Bastos; João Paulo Oliveira
Journal:  JIMD Rep       Date:  2012-03-24

Review 5.  Enzyme replacement therapy and beyond-in memoriam Roscoe O. Brady, M.D. (1923-2016).

Authors:  Markus Ries
Journal:  J Inherit Metab Dis       Date:  2017-03-17       Impact factor: 4.982

6.  Cognitive function in adults aging with fabry disease: a case-control feasibility study using telephone-based assessments.

Authors:  Virginia G Wadley; Leslie A McClure; David G Warnock; Caroline L Lassen-Greene; Robert J Hopkin; Dawn A Laney; Virginia M Clarke; Manjula Kurella Tamura; George Howard; Katherine Sims
Journal:  JIMD Rep       Date:  2015-01-08

7.  The pulvinar sign: frequency and clinical correlations in Fabry disease.

Authors:  Alessandro P Burlina; Renzo Manara; Catherine Caillaud; Jean-Pierre Laissy; Mariasavina Severino; Isabelle Klein; Alberto Burlina; Olivier Lidove
Journal:  J Neurol       Date:  2008-02-26       Impact factor: 4.849

Review 8.  Fabry disease-often seen, rarely diagnosed.

Authors:  Björn Hoffmann; Ertan Mayatepek
Journal:  Dtsch Arztebl Int       Date:  2009-06-26       Impact factor: 5.594

9.  Ear symptoms in children with Fabry disease: data from the Fabry Outcome Survey.

Authors:  A Keilmann; D Hajioff; U Ramaswami
Journal:  J Inherit Metab Dis       Date:  2009-10-27       Impact factor: 4.982

10.  Fabry heterozygote mimicking multiple sclerosis.

Authors:  Wai Yan Yau; Marzena J Fabis-Pedrini; Allan G Kermode
Journal:  BMJ Case Rep       Date:  2017-06-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.